Tuesday, September 4, 2018


LIVN LivaNova PLC gains 18% Sep 4, 2018

LivaNova PLC, a medical technology company, design, develops, manufactures, and sells therapeutic solutions worldwide. It operates in three segments: Neuromodulation, Cardiac Surgery, and Cardiac Rhythm Management. The Neuromodulation segment designs, develops, and markets vagus nerve stimulation (VNS) therapy system, an implantable device for the treatment of drug-resistant epilepsy and treatment-resistant depression, as well as develops transcutaneous VNS devices. This segment serves neurologists, neurosurgeons, hospitals and healthcare systems, and government health departments. The Cardiac Surgery segment develops, produces, and sells cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves primarily for perfusionists and cardiac surgeons. The Cardiac Rhythm Management segment develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failures. This segment offers implantable cardiac pacemakers, cardioverter defibrillators, cardiac resynchronization therapy devices, and patient management tools primarily for electrophysiologists, implanting cardiologists, heart failure specialists, and cardiac surgeons. This segment also develops VITARIA systems for the treatment of chronic heart failure. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive